BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/29/2016 5:11:00 PM | Browse: 1532 | Download: 2744
Publication Name World Journal of Dermatology
Manuscript ID 22381
Country Netherlands
ISSN 2218-6190 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pediatrics
Manuscript Type Review
Article Title Propranolol for infantile hemangioma: Current state of affairs
Manuscript Source Invited Manuscript
All Author List Andre V Moyakine and Carine JM van der Vleuten
Funding Agency and Grant Number
Corresponding Author Andre V Moyakine, MD, Department of Dermatology, Hecovan Expertise Centre for Hemangioma and Vascular Malformations, Radboud University Medical Centre, PO box 9101, Nijmegen, 6500 HB Gelderland, The Netherlands. andre.moyakine@radboudumc.nl
Key Words Infantile hemangioma; Propranolol; Beta-blocker; Adverse effect; Development
Core Tip The discovery that propranolol is efficacious in the treatment of infantile hemangioma (IH) has led to an upsurge in publications, increasing our knowledge of this subject. In this review, we provide the most up-to-date information on the pathophysiology, variations in clinical presentation, and natural history of IH. We look at possible working mechanisms of several treatments and the current concerns regarding the treatment of first choice, propranolol. Finally, we provide an overview of instruments, measuring IH severity and/or activity and IH-related quality of life.
Publish Date 2016-01-29 17:09
Citation Moyakine AV, van der Vleuten CJM. Propranolol for infantile hemangioma: Current state of affairs. World J Dermatol 2016; 5(1): 4-16
URL http://www.wjgnet.com/2218-6190/full/v5/i1/4.htm
DOI http://dx.doi.org/10.5314/wjd.v5.i1.4
Full Article (PDF) WJD-5-4.pdf
Full Article (Word) WJD-5-4.doc